Jump to content

LSD-Quinoline

Add links
From Wikipedia, the free encyclopedia
LSD-Quinoline
Clinical data
Drug classSerotonin receptor agonist; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • (7aR,10R)-N,N-diethyl-8-methyl-7a,8,9,10-tetrahydro-7H-quinolino[7,6,5-de]quinoline-10-carboxamide
Chemical and physical data
FormulaC21H25N3O
Molar mass335.451 g·mol−1
3D model (JSmol)
  • CCN(C([C@@H](C1)C=C2C3=C4C(C[C@@]2([H])N1C)=CC=NC4=CC=C3)=O)CC
  • InChI=1S/C21H25N3O/c1-4-24(5-2)21(25)15-11-17-16-7-6-8-18-20(16)14(9-10-22-18)12-19(17)23(3)13-15/h6-11,15,19H,4-5,12-13H2,1-3H3/t15-,19-/m1/s1
  • Key:JKMAOHMIUIWQHW-DNVCBOLYSA-N

LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E. Olson and colleagues. It acts as a moderately selective serotonin receptor agonist, primarily at the serotonin 5-HT2A receptor, though its activity at other subtypes such as the 5-HT2B and 5-HT2C receptors, and at other targets of LSD such as dopamine receptors, has not been published. It was developed in the course of resarch into non-hallucinogenic psychoplastogens, and is described as having around 24x lower potency than LSD and with "reduced hallucinogenic potential", though this would suggest it may still be of a similar potency to many psychedelic tryptamine derivatives. It has been researched for therapeutic applications including as a potential antidepressant. LSD-Quinoline was first described in the scientific literature by 2026.[1][2]

See also

[edit]

References

[edit]
  1. ↑ DeMuynck BM, Hyland EE, Kim H, Menches VL, Vernier AM, Wang Z, Olson DE, Levin MD, Nagib DA (August 2026). "Skeletal editing by iron-catalyzed carbene insertion of trichloromethanes" (PDF). Chem. 12 (8). doi:10.1016/j.chempr.2026.102968. PMC 13528700. PMID 42677223.
  2. ↑ Basargin AG, Domokosa A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, Krüger J, Dunlap LE, Carter SJ, Rebek IA, McKee JL, Schalk SS, Liu M, Fettinger JC, Gonzalez MA, Potluri A, Tantillo DJ, Fiehn O, McCorvy JD, Olson DE (September 2026). "Deconstruction of lysergic acid diethylamide". Proceedings of the National Academy of Sciences of the United States of America. 123 (38) e2603412123. doi:10.1073/pnas.2603412123. PMID 42709856.
Retrieved from "https://en.wikipedia.org/w/index.php?title=LSD-Quinoline&oldid=1374730835"